Treatment Update in Systemic Lupus Erythematous

被引：11
作者：
Hoi, Alberta Y. [1 ,2 ]
Morand, Eric F. [1 ,2 ]
机构：
[1] Monash Univ, Ctr Inflammatory Dis, Clayton, Vic, Australia
[2] Monash Hlth, Dept Rheumatol, 246 Clayton Rd, Clayton, Vic 3168, Australia
来源：
RHEUMATIC DISEASE CLINICS OF NORTH AMERICA | 2021年 / 47卷 / 03期
关键词：
Lupus; Treatment target; Lupus low disease activity state; Lupus nephritis; Mycophenolate; Euro-lupus; Anifrolumab; Belimumab; DISEASE-ACTIVITY STATE; LONG-TERM OUTCOMES; MYCOPHENOLATE-MOFETIL; DOUBLE-BLIND; MULTITARGET THERAPY; INDUCTION TREATMENT; NEPHRITIS; HYDROXYCHLOROQUINE; EFFICACY; RITUXIMAB;
D O I：
10.1016/j.rdc.2021.04.012
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：513 / 530
页数：18
相关论文
共 87 条
[1]   The Early Protective Effect of Hydroxychloroquine on the Risk of Cumulative Damage in Patients with Systemic Lupus Erythematosus [J].
Akhavan, Pooneh S. ;
Su, Jiandong ;
Lou, Wendy ;
Gladman, Dafna D. ;
Urowitz, Murray B. ;
Fortin, Paul R. .
JOURNAL OF RHEUMATOLOGY, 2013, 40 (06) :831-841
[2]   Remission and low disease activity state (LDAS) are protective of intermediate and long-term outcomes in SLE patients. Results from LUMINA (LXXVIII), a multiethnic, multicenter US cohort [J].
Alarcon, G. S. ;
Ugarte-Gil, M. F. ;
Pons-Estel, G. ;
Vila, L. M. ;
Reveille, J. D. ;
McGwin, G. .
LUPUS, 2019, 28 (03) :423-426
[3]   Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus:: Data from LUMINA, a multiethnic US cohort (LUMINA L) [J].
Alarcon, Graciela S. ;
McGwin, Gerald ;
Bertoli, Ana M. ;
Fessler, Barri J. ;
Calvo-Alen, Jaime ;
Bastian, Holly M. ;
Vila, Luis M. ;
Reveille, John D. .
ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 (09) :1168-1172
[4]  
Apostolopoulos D., 2019, LANCET RHEUMATOL, P1
[5]   Mycophenolate Mofetil versus Cyclophosphamide for Induction Treatment of Lupus Nephritis [J].
Appel, Gerald B. ;
Contreras, Gabriel ;
Dooley, Mary Anne ;
Ginzler, Ellen M. ;
Isenberg, David ;
Jayne, David ;
Li, Lei-Shi ;
Mysler, Eduardo ;
Sanchez-Guerrero, Jorge ;
Solomons, Neil ;
Wofsy, David .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2009, 20 (05) :1103-1112
[6]   Phase II Randomized Trial of Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis [J].
Atisha-Fregoso, Yemil ;
Malkiel, Susan ;
Harris, Kristina M. ;
Byron, Margie ;
Ding, Linna ;
Kanaparthi, Sai ;
Barry, William T. ;
Gao, Wendy ;
Ryker, Kristin ;
Tosta, Patti ;
Askanase, Anca D. ;
Boackle, Susan A. ;
Chatham, W. Winn ;
Kamen, Diane L. ;
Karp, David R. ;
Kirou, Kyriakos A. ;
Sam Lim, S. ;
Marder, Bradley ;
McMahon, Maureen ;
Parikh, Samir V. ;
Pendergraft, William F., III ;
Podoll, Amber S. ;
Saxena, Amit ;
Wofsy, David ;
Diamond, Betty ;
Smilek, Dawn E. ;
Aranow, Cynthia ;
Dall'Era, Maria .
ARTHRITIS & RHEUMATOLOGY, 2021, 73 (01) :121-131
[7]   Controlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematosus [J].
Barile-Fabris, L ;
Ariza-Andraca, R ;
Olguín-Ortega, L ;
Jara, LJ ;
Fraga-Mouret, A ;
Miranda-Limón, JM ;
de la Mata, JF ;
Clark, P ;
Vargas, F ;
Alcocer-Varela, J .
ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 (04) :620-625
[8]   Tacrolimus is safe and effective in patients with severe steroid-refractory or steroid-dependent inflammatory bowel disease - A long-term follow-up [J].
Baumgart, Daniel C. ;
Pintoffl, Jan P. ;
Sturm, Andreas ;
Wiedenmann, Bertram ;
Dignass, Axel U. .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2006, 101 (05) :1048-1056
[9]  
Bos JD, 2003, EUR J DERMATOL, V13, P455
[10]   Glucocorticoids in the treatment of rheumatic diseases - An update on the mechanisms of action [J].
Buttgereit, F ;
Straub, RH ;
Wehling, M ;
Burmester, GR .
ARTHRITIS AND RHEUMATISM, 2004, 50 (11) :3408-3417
123456789